Business
THC Farmaceuticals Completes Acquisition of Majority Ownership of CBDual Biotechnology Corp; Applies for Provisional Patent
THC Farmaceuticals Completes Acquisition of Majority Ownership of CBDual Biotechnology Corp; Applies for Provisional Patent.
About this update from Thc Farmaceuticals, Inc
[{"type":"text","content":"Thousand Oaks, CA /ACCSESSWIRE/ THC Farmaceuticals, Inc (OTC:CBDG) today announced that it consummated its acquisition of a majority ownership in CBDual Biotechnology Corp. CBDual is a Cannabis Biotechnology start-up company focused on developing products based on cannabidiol (CBD) and/or Tetrahydrocannabinol (THC). The company’s facility is located in southern California, providing easy access for patients to participate in clinical trials of new medical cannabis medications, therapies, and products.Per the agreement, CBDG has begun funding CBDual $250,000 USD, and has issued CBDual 1,500,000 of its common shares to CBDual to complete the first phase of this acquisition. As CBDual meets certain benchmarks, including revenues, patent applications, and registration with, and subsequent approvals from the US FDA, CBDG will acquire up to 100% of CBDual by issuing CBDual’s founders, additional shares of CBDG.About CBDual Biotechnology Corp.CBDual Biotechnology Corp is a privately held, US Based Biotechnology company with propriety technology for enhanced oral delivery of bioactive cannabindoids and other delivery methods. This technology promotes overall oral health due to higher effectiveness of the delivery methodology. The company was founded in 2016 and is headquartered in California, with its R&D in the US and Israel. For More information about CBDual, please visit the website: www.CBDual.comProvisional Patent ApplicationCBDual’s founder, Dr. Greg Rubin filed a provisional patent which utilizes a unique combination of cannabinoids and other non-toxic efficacious ingredients inside intradermal tattoos, including permanent makeup inks. Dr Rubin filed this provisional patent application on behalf of and to be owned by CBDual. It is designed, once produced and distributed by CBDual to provide new generation of tattoo inks containing a unique organic ingredients and cannabinoids to address two of the most common complications of the tattoo application -pain and aftercare complications and inflammation. This new inks will provide tattoo artists with a medical solution that will make the often painful experience for tattoo clientele, a safer and cozier experience. This is the first in a series of inventions CBDual will patent for production and distribution in the future.About THC Farmaceuticals, Inc.THC Farmaceuticals, Inc.: (OTC...